Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$98.83 AUD
Change Today -0.13 / -0.13%
Volume 870.0K
CSL On Other Exchanges
Symbol
Exchange
OTC US
Munich
OTC US
Frankfurt
As of 2:10 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CSL) Snapshot

Open
A$99.55
Previous Close
A$98.96
Day High
A$99.90
Day Low
A$98.30
52 Week High
08/3/15 - A$99.90
52 Week Low
08/8/14 - A$63.77
Market Cap
45.9B
Average Volume 10 Days
1.3M
EPS TTM
A$2.83
Shares Outstanding
464.8M
EX-Date
03/16/15
P/E TM
25.4x
Dividend
A$1.39
Dividend Yield
1.41%
Current Stock Chart for CSL LTD (CSL)

Related News

No related news articles were found.

csl ltd (CSL) Related Businessweek News

View More BusinessWeek News

csl ltd (CSL) Details

CSL Limited is engaged in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including vaccines to protect against viral and bacterial diseases; pharmaceuticals to treat a range of human medical conditions; diagnostic products to determine compatibility of donor-recipient blood in transfusion settings; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment is engaged in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

12,196 Employees
Last Reported Date: 08/12/14
Founded in 1916

csl ltd (CSL) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: $3.1M
Chief Financial Officer
Total Annual Compensation: $1.6M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.2M
Executive Vice President of Manufacturing Ope...
Total Annual Compensation: $1.1M
Executive Vice President of Legal, Group Gene...
Total Annual Compensation: $998.2K
Compensation as of Fiscal Year 2014.

csl ltd (CSL) Key Developments

BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited

BioCryst Pharmaceuticals, Inc. announced that it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited. RAPIVAB is an intravenous (I.V.) treatment indicated in the U.S. for acute uncomplicated influenza in adults 18 years and older. It is also currently licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world. RAPIVAB will be commercialized by CSL's subsidiary, bioCSL, which specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets. Under the terms of the agreement, bioCSL obtains worldwide rights to commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retains all rights to pursue pandemic stockpiling orders for RAPIVAB from the U.S. government, while bioCSL is responsible for government stockpiling outside the U.S. Under the terms of the agreement, BioCryst will receive an upfront payment of $33.7 million from bioCSL, and may receive up to $12.0 million in additional payments related to the successful achievement of certain regulatory milestones. BioCryst will receive tiered royalties that are contingent upon certain net sales thresholds in the U.S. and the rest of the world, as well as a percentage of proceeds from government stockpiling purchases outside the U.S. In addition, bioCSL will purchase existing and in-process inventory of RAPIVAB for treatment of influenza patients in upcoming flu seasons.

G. Naylor to Lead CSL Limited's New Influenza Vaccine Business Planned for Launch at the Start of 2016

CSL Limited announced that Gordon Naylor will lead CSL's new global influenza vaccine business, which is planned for launch at the start of 2016. Mr. Naylor is currently the Company's Chief Financial Officer and has held executive management responsibility for CSL's existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012.

CSL Ltd. Presents at Credit Suisse 18th Annual Asian Investment Conference 2015, Mar-23-2015

CSL Ltd. Presents at Credit Suisse 18th Annual Asian Investment Conference 2015, Mar-23-2015 . Venue: Conrad Hotel, Pacific Place, 88 Queensway, Hong Kong, Hong Kong.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSL:AU A$98.83 AUD -0.13

CSL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,922 JPY +54.50
Green Cross Corp/South Korea 212,500 KRW -7,500.00
Grifols SA €40.59 EUR +0.40
Shire PLC 5,730 GBp +50.00
Solvay SA €120.20 EUR -1.55
View Industry Companies
 

Industry Analysis

CSL

Industry Average

Valuation CSL Industry Range
Price/Earnings 25.6x
Price/Sales 6.2x
Price/Book 11.4x
Price/Cash Flow 24.8x
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit www.csl.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.